Results 161 to 170 of about 6,141,684 (256)

Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. [PDF]

Med Sci (Basel)
Fortoeș D, Antohe I, Cianga VA, Minciună CD, Nicorici E, Dolachi-Pelin E, Zlei M, Mentel M, Dragoș L, Ivanov I, Uhl A, Tomuleasa C, Dăscălescu A.   +12 more
europepmc   +1 more source

Distinct Clinical Features of Multiple Myeloma With t(11;14): A Post Hoc Analysis of JSH‐MM‐15 Study

Cancer Science, EarlyView.
t(11;14)‐positive MM is a clinically distinct subgroup characterized by intermediate prognostic risk, modest response depth, and treatment‐dependent outcomes. ABSTRACT t(11;14) (q13;q32) occurs in approximately 15%–25% of multiple myeloma (MM) cases and has traditionally been regarded as a standard cytogenetic risk factor.
Taku Tsukamoto, Yuji Shimura, Shinsuke Mizutani, Takahiro Fujino, Haruya Okamoto, Mitsuhiro Itagaki, Hiroshi Handa, Takayuki Shimizu, Morio Sawamura, Tadao Ishida, Satoru Kosugi, Shuichi Ota, Makoto Yoshimitsu, Yutaka Shimazu, Isamu Sugiura, Hirohiko Shibayama, Shin‐ichi Fuchida, Hiroyuki Takamatsu, Akiko M. Saito, Hitoshi Kiyoi, Koichi Akashi, Itaru Matsumura, Akifumi Takaori‐Kondo, Junya Kuroda, Shinsuke Iida   +24 more
wiley   +1 more source

Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes. [PDF]

Bone Marrow Transplant
Rodríguez-Lobato LG, de Daniel A, Carro Arostegui I, Arribas Castro I, Gironella M, Verge J, Escoda L, Tolosa C, Martí-Tutusaus JM, Baca C, Abella E, Motlló C, López-Pardo J, Oriol A, Castillo-Girón C, Tovar N, Rosiñol L, Cibeira MT, Sureda A, Fernández de Larrea C.   +19 more
europepmc   +1 more source

Outcomes of refractory and early‐relapsed large B‐cell lymphoma patients after first‐line treatment in the prospective Real‐world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre‐CAR T era

British Journal of Haematology, EarlyView.
Stéphanie Guidez, Aurélien Belot, Fanny Cherblanc, Bastien Lesné, Sylvain Carras, Catherine Thieblemont, Fontanet Bijou, Cédric Rossi, Luc Mathieu Fornecker, Jehan Dupuis, Krimo Bouabdallah, Ludovic Fouillet, Adrien Chauchet, Benoit Tessoulin, Loic Ysebaert, Alice Pauc, Pascale Cony‐Makhoul, Remy Gressin, Gaelle Laboure, Antoine Bonnet, Sandy Amorim, Christophe Fruchart, Roch Houot, Gian Matteo Pica, Carole Soussain, Sophie Dennetiere, Cécile Leyronnas, Pauline Lionne‐Huyghe, Hervé Ghesquières, Pierre Sesques   +29 more
wiley   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

Cancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source

Autologous stem cell transplantation for secondary central nervous system lymphoma: a multicentre retrospective analysis. [PDF]

BMC Cancer
Tan MW, Ling V, Tan JY, Chan WL, Thong E, Nagarajan C, Ong SY, Chen Y, Lim FL, Goh YT, Hwang WY, Ho AY, Koh LP, Tan LK, Lee J, Chan EH, de Mel S, Poon ML, Ng LC.   +18 more
europepmc   +1 more source

Liver Organoids: From Disease Modelling to Regenerative Medicine

Cell Proliferation, EarlyView.
Liver organoids provide a versatile platform for disease modelling and drug discovery, leveraging stem cells and engineering techniques. They bridge research and clinical applications, offering significant potential for advancing precision medicine and regenerative therapies for liver diseases.
Tiepeng Wang, Xiaotian Qu, Jinhong Si, Junkang Meng, Ting Zhang, Shuliang Niu   +5 more
wiley   +1 more source

Myeloma-Associated Sporadic Late-Onset Nemaline Myopathy, Successfully Treated with Daratumumab Based Induction and Autologous Stem Cell Transplantation: A Case Report. [PDF]

EJHaem
Moriwaki K, Kawano Y, Nakajima M, Nishimura N, Ueda M, Yasunaga JI.   +5 more
europepmc   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation. [PDF]

Cancer
Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria BR, Godby KN, Bal S, Huls F, Silbermann RW, Costa LJ.   +9 more
europepmc   +1 more source